1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
3
|
Junttila MR and de Sauvage FJ: Influence
of tumour micro- environment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
5
|
Ringel J and Löhr M: The MUC gene family:
Their role in diagnosis and early detection of pancreatic cancer.
Mol Cancer. 2:92003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bhatia R, Gautam SK, Cannon A, Thompson C,
Hall BR, Aithal A, Banerjee K, Jain M, Solheim JC, Kumar S and
Batra SK: Cancer-associated mucins: Role in immune modulation and
metastasis. Cancer Metastasis Rev. 38:223–236. 2019. View Article : Google Scholar : PubMed/NCBI
|
7
|
Li W, Han Y, Sun C, Li X, Zheng J, Che J,
Yao X and Kufe D: Novel insights into the roles and therapeutic
implications of MUC1 oncoprotein via regulating proteins and
non-coding RNAs in cancer. Theranostics. 12:999–1011. 2022.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Nabavinia MS, Gholoobi A, Charbgoo F,
Nabavinia M, Ramezani M and Abnous K: Anti-MUC1 aptamer: A
potential opportunity for cancer treatment. Med Res Rev.
37:1518–1539. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang
L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1
carcinoma-associated protein confers resistance to genotoxic
anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Nath S and Mukherjee P: MUC1: A
multifaceted oncoprotein with a key role in cancer progression.
Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ye J, Wei X, Shang Y, Pan Q, Yang M, Tian
Y, He Y, Peng Z, Chen L, Chen W and Wang R: Core 3 mucin-type
O-glycan restoration in colorectal cancer cells promotes
MUC1/p53/miR-200c-dependent epithelial identity. Oncogene.
36:6391–6407. 2017. View Article : Google Scholar : PubMed/NCBI
|
12
|
Roy LD, Sahraei M, Subramani DB, Besmer D,
Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, et al:
MUC1 enhances invasiveness of pancreatic cancer cells by inducing
epithelial to mesenchymal transition. Oncogene. 30:1449–1459. 2011.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han
W and Zhang YQ: Expression of MUC1 and its significance in
hepatocellular and cholangiocarcinoma tissue. World J
Gastroenterol. 11:4661–4666. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Liu L, Gu M, Ma J, Wang Y, Li M, Wang H,
Yin X and Li X: CircGPR137B/miR-4739/FTO feedback loop suppresses
tumorigenesis and metastasis of hepatocellular carcinoma. Mol
Cancer. 21:1492022. View Article : Google Scholar : PubMed/NCBI
|
15
|
Liu W, Zheng L, Zhang R, Hou P, Wang J, Wu
L and Li J: Circ-ZEB1 promotes PIK3CA expression by silencing
miR-199a-3p and affects the proliferation and apoptosis of
hepatocellular carcinoma. Mol Cancer. 21:722022. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma
JZ, Sun SH, Yang F and Zhou WP: Circular RNA cSMARCA5 inhibits
growth and metastasis in hepatocellular carcinoma. J Hepatol.
68:1214–1227. 2018. View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ and
Xu RH: Circular RNA: Metabolism, functions and interactions with
proteins. Mol Cancer. 19:1722020. View Article : Google Scholar : PubMed/NCBI
|
18
|
Ni J, Bucci J, Chang L, Malouf D, Graham P
and Li Y: Targeting MicroRNAs in prostate cancer radiotherapy.
Theranostics. 7:3243–3259. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Han B, Chao J and Yao H: Circular RNA and
its mechanisms in disease: From the bench to the clinic. Pharmacol
Ther. 187:31–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
20
|
Kristensen LS, Jakobsen T, Hager H and
Kjems J: The emerging roles of circRNAs in cancer and oncology. Nat
Rev Clin Oncol. 19:188–206. 2022. View Article : Google Scholar : PubMed/NCBI
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Patel KN, Maghami E, Wreesmann VB, Shaha
AR, Shah JP, Ghossein R and Singh B: MUC1 plays a role in tumor
maintenance in aggressive thyroid carcinomas. Surgery.
138:994–1002. 2005. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lucarelli G, Netti GS, Rutigliano M,
Lasorsa F, Loizzo D, Milella M, Schirinzi A, Fontana A, Di Serio F,
Tamma R, et al: MUC1 expression affects the immunoflogosis in renal
cell carcinoma microenvironment through complement system
activation and immune infiltrate modulation. Int J Mol Sci.
24:48142023. View Article : Google Scholar : PubMed/NCBI
|
24
|
Schroeder JA, Adriance MC, Thompson MC,
Camenisch TD and Gendler SJ: MUC1 alters beta-catenin-dependent
tumor formation and promotes cellular invasion. Oncogene.
22:1324–1332. 2003. View Article : Google Scholar : PubMed/NCBI
|
25
|
Yuan H, Wang J, Wang F, Zhang N, Li Q, Xie
F, Chen T, Zhai R, Wang F, Guo Y, et al: Mucin 1 gene silencing
inhibits the growth of SMMC-7721 human hepatoma cells through
Bax-mediated mitochondrial and caspase-8-mediated death receptor
apoptotic pathways. Mol Med Rep. 12:6782–6788. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Bose M and Mukherjee P: Microbe-MUC1
crosstalk in cancer-associated infections. Trends Mol Med.
26:324–336. 2020. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wang J, Ni WH, Hu KB, Zhai XY, Xie F, Jie
J, Zhang NN, Jiang LN, Yuan HY and Tai GX: Targeting MUC1 and JNK
by RNA interference and inhibitor inhibit the development of
hepatocellular carcinoma. Cancer Sci. 108:504–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Bozkaya G, Korhan P, Cokaklı M, Erdal E,
Sağol O, Karademir S, Korch C and Atabey N: Cooperative interaction
of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol
Cancer. 11:642012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Apostolopoulos V, Stojanovska L and
Gargosky SE: MUC1 (CD227): A multi-tasked molecule. Cell Mol Life
Sci. 72:4475–4500. 2015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Carson DD: The cytoplasmic tail of MUC1: A
very busy place. Sci Signal. 1:pe352008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Supruniuk K and Radziejewska I: MUC1 is an
oncoprotein with a significant role in apoptosis (review). Int J
Oncol. 59:682021. View Article : Google Scholar : PubMed/NCBI
|
32
|
Villanueva L, Álvarez-Errico D and
Esteller M: The contribution of epigenetics to cancer
immunotherapy. Trends Immunol. 41:676–691. 2020. View Article : Google Scholar : PubMed/NCBI
|
33
|
Winkle M, El-Daly SM, Fabbri M and Calin
GA: Noncoding RNA therapeutics-challenges and potential solutions.
Nat Rev Drug Discov. 20:629–651. 2021. View Article : Google Scholar : PubMed/NCBI
|
34
|
Wang N, Zheng J, Chen Z, Liu Y, Dura B,
Kwak M, Xavier-Ferrucio J, Lu YC, Zhang M, Roden C, et al:
Single-cell microRNA-mRNA co-sequencing reveals non-genetic
heterogeneity and mechanisms of microRNA regulation. Nat Commun.
10:952019. View Article : Google Scholar : PubMed/NCBI
|
35
|
Wang L, Zhang Z and Wang FS: The efficacy
of miRNA122, a novel therapeutic target, for predicting the
progression of hepatocellular carcinoma (HCC). Cell Mol Immunol.
9:103–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
36
|
Bandiera S, Pfeffer S, Baumert TF and
Zeisel MB: miR-122-a key factor and therapeutic target in liver
disease. J Hepatol. 62:448–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
37
|
Nakao K, Miyaaki H and Ichikawa T:
Antitumor function of microRNA-122 against hepatocellular
carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
38
|
Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z,
Liu J, Cui Y, Bian X, Bie P and Qian C: MicroRNA-122 sensitizes HCC
cancer cells to adriamycin and vincristine through modulating
expression of MDR and inducing cell cycle arrest. Cancer Lett.
310:160–169. 2011.PubMed/NCBI
|
39
|
Luna JM, Barajas JM, Teng KY, Sun HL,
Moore MJ, Rice CM, Darnell RB and Ghoshal K: Argonaute CLIP defines
a deregulated miR-122-bound transcriptome that correlates with
patient survival in human liver cancer. Mol Cell. 67:400–410.e7.
2017. View Article : Google Scholar : PubMed/NCBI
|
40
|
Chen S, Zhang Y, Ding X and Li W:
Identification of lncRNA/circRNA-miRNA-mRNA ceRNA network as
biomarkers for hepatocellular carcinoma. Front Genet.
13:8388692022. View Article : Google Scholar : PubMed/NCBI
|
41
|
Singh D, Kesharwani P, Alhakamy NA and
Siddique HR: Accentuating CircRNA-miRNA-transcription factors axis:
A conundrum in cancer research. Front Pharmacol. 12:7848012022.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Xiong DD, Dang YW, Lin P, Wen DY, He RQ,
Luo DZ, Feng ZB and Chen G: A circRNA-miRNA-mRNA network
identification for exploring underlying pathogenesis and therapy
strategy of hepatocellular carcinoma. J Transl Med. 16:2202018.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Li D, Guan M, Cao X, Zha ZQ, Zhang P,
Xiang H, Zhou Y, Peng Q, Xu Z, Lu L and Liu G: GFPT1 promotes the
proliferation of cervical cancer via regulating the ubiquitination
and degradation of PTEN. Carcinogenesis. 43:969–979. 2022.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Gong Y, Qian Y, Luo G, Liu Y, Wang R, Deng
S, Cheng H, Jin K, Ni Q, Yu X, et al: High GFPT1 expression
predicts unfavorable outcomes in patients with resectable
pancreatic ductal adenocarcinoma. World J Surg Oncol. 19:352021.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Zhang C, Lian H, Xie L, Yin N and Cui Y:
LncRNA ELFN1-AS1 promotes esophageal cancer progression by
up-regulating GFPT1 via sponging miR-183-3p. Biol Chem.
401:1053–1061. 2020. View Article : Google Scholar : PubMed/NCBI
|